Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia.

BACKGROUND The clinical efficacy and tolerability of linezolid were demonstrated in a previously published, randomized, double-blind, registration study comparing linezolid with vancomycin for the empiric treatment of 396 patients with nosocomial pneumonia. OBJECTIVES The aims of this study were to obtain additional experience with linezolid and vancomycin in patients with nosocomial pneumonia and to satisfy international regulatory requirements. METHODS Patients with pneumonia acquired after 48 hours in an inpatient facility were randomly assigned to receive either IV linezolid 600 mg or IV vancomycin 1 g every 12 hours for 7 to 21 consecutive days. Patients also received IV aztreonam 1 to 2 g every 8 hours, which could be discontinued if gram-negative pathogens were not identified. The primary efficacy variables were clinical and microbiologic outcomes in evaluable patients at the follow-up visit 15 to 21 days after the end of therapy. Results from the continuation study were analyzed separately and did not include patients from the previously reported study. RESULTS A total of 623 patients were enrolled: 321 in the linezolid group and 302 in the vancomycin group. Mean (SD) ages were 63.1 (19.1) years and 61.9 (19.3) years, respectively. Mean (SD) Acute Physiology and Chronic Health Evaluation II scores were 14.1 (5.8) and 14.1 (6.2), respectively. There were no significant differences between the linezolid and vancomycin groups at the follow-up visit in clinical cure rates (114/168 [67.9%] and 111/171 [64.9%]) or microbiologic success rates (47/76 [61.8%] and 42/79 [53.2%]) in evaluable patients (excluding those who had indeterminate or missing outcomes). There were also no significant differences in the rates of all drug-related adverse events (14.0% and 14.0%) or those that occurred in > 1% of patients, including diarrhea (3.7% and 3.0%), nausea (0.3% and 1.3%), and rash (0.6% and 1.7%) in the linezolid and vancomycin groups, respectively. CONCLUSION In the population studied, linezolid appeared to be as well tolerated and as effective as vancomycin, each in combination with aztreonam.

[1]  J. Chastre,et al.  Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  R. Gaynes,et al.  Nosocomial Infections in Combined Medical-Surgical Intensive Care Units in the United States , 2000, Infection Control & Hospital Epidemiology.

[3]  J. Maillet,et al.  Hospital-acquired pneumonia: methicillin resistance and intensive care unit admission. , 1998, The American journal of medicine.

[4]  M. Zervos,et al.  Thrombocytopenia associated with linezolid therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  T. Fabian,et al.  Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. , 2000, American journal of respiratory and critical care medicine.

[6]  J. Kilburn,et al.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents , 1996, Antimicrobial agents and chemotherapy.

[7]  E Rubinstein,et al.  Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  L. Mandell,et al.  Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: A consensus statement , 1996 .

[9]  G. Eliopoulos,et al.  In vitro activities in new oxazolidinone antimicrobial agents against enterococci , 1996, Antimicrobial agents and chemotherapy.

[10]  Jerome J. Schentag Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. , 1999, Journal of chemotherapy.

[11]  L. Peterson,et al.  In Vitro Activities of Linezolid against Important Gram-Positive Bacterial Pathogens Including Vancomycin-Resistant Enterococci , 1999, Antimicrobial Agents and Chemotherapy.

[12]  M. Rybak,et al.  Outcome Assessment of Minimizing Vancomycin Monitoring and Dosing Adjustments , 1999, Pharmacotherapy.

[13]  R. Moellering Monitoring serum vancomycin levels: climbing the mountain because it is there? , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  A P MacGowan,et al.  Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. , 2002, The Journal of antimicrobial chemotherapy.

[15]  Hajo A. Bruining,et al.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. , 1995 .

[16]  H. Aoki,et al.  The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria , 1998, Antimicrobial Agents and Chemotherapy.

[17]  Jerome J. Schentag,et al.  Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[18]  S. Schichman,et al.  Linezolid-induced pure red blood cell aplasia. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  P. Lietman,et al.  Serum vancomycin concentrations: reappraisal of their clinical value. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  G. Tillotson,et al.  Hematologic Effects of Antimicrobials: Focus on the Oxazolidinone Linezolid , 2001, Pharmacotherapy.

[21]  J. S. Daly,et al.  Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound , 1988, Antimicrobial Agents and Chemotherapy.

[22]  D. Wilson,et al.  In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections , 1996, Antimicrobial agents and chemotherapy.